EUVIMEDEUVIMED entdecken
Leitlinie

Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections – Timing of Intravenous to Oral Antibiotics Transition for Complicated Urinary Tract Infections

Barbara W Trautner iD, Nicolás W Cortés-Penfield, Kalpana Gupta, Elizabeth B Hirsch, Molly Horstman, Gregory J Moran, Richard Colgan, John C O'Horo, Muhammad S Ashraf, Shannon Connolly, Dimitri Drekonja, Larissa Grigoryan iD und 6 weitere

Clinical Infectious Diseases · 24.08.2026 · 82 (Supplement_3) · i68-i78

DOI: 10.1093/cid/ciaf461 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 19.12.2025. Verfasst von Barbara W Trautner und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Urinary Tract Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 66 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

These recommendations provide guidance on the optimal timing for transitioning from intravenous to oral antibiotics in patients with complicated urinary tract infection (cUTI), especially in presence of associated Gram-negative bacteremia.

Methods

The panel's recommendations are based upon evidence derived from systematic literature reviews which focused on comparative benefits and harms of transitioning to oral therapy versus continuing parenteral therapy of the total duration of treatment, including publications since 2000. These recommendations adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach.

Results

The guidelines panel suggests transitioning to oral antibiotics in patients with cUTI who are clinically improving, able to take medication, and for whom an effective oral option is available, rather than continuing parenteral therapy for the remaining treatment duration, regardless of the presence of associated Gram-negative bacteremia. An effective oral option needs to be active against the causative pathogen and achieve therapeutic levels in the urine and relevant tissue.

Conclusions

Parenteral and oral antibiotics used to complete treatment courses for cUTI provide similar efficacy and adverse events, especially in the context of shorter duration of therapy. This recommendation places a high value on reducing avoidable intravenous catheter-related adverse events, costs, and resources, as well as taking into account practical aspects of antibiotic administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsUrinary Tract InfectionsHumansAdministration, OralAdministration, IntravenousBacteremiaGram-Negative Bacterial Infections

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Section of Infectious Diseases, Boston VA Health Care System, Boston University School of Medicine, Boston, Massachusetts, USA.
  • Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA.
  • Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey VA Medical Center, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Clinical Emergency Medicine, David Geffen School of Medicine at UCLA, Olive View-UCLA Medical Center, Los Angeles, California, USA.

ORCID-Profile: Barbara W Trautner, Larissa Grigoryan, Anthony Schaeffer

Zitieren

APA

Trautner, B. W., Cortés-Penfield, N. W., Gupta, K., Hirsch, E. B., Horstman, M., Moran, G. J., Colgan, R., O'Horo, J. C., Ashraf, M. S., Connolly, S., Drekonja, D., Grigoryan, L., Huttner, A., Lazenby, G. B., Nicolle, L., Schaeffer, A., Yawetz, S., & Lavergne, V. (2026). Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections – Timing of Intravenous to Oral Antibiotics Transition for Complicated Urinary Tract Infections. Clinical Infectious Diseases, 82(Supplement_3), i68-i78. https://doi.org/10.1093/cid/ciaf461

Vancouver

Trautner BW, Cortés-Penfield NW, Gupta K, Hirsch EB, Horstman M, Moran GJ, et al. Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections – Timing of Intravenous to Oral Antibiotics Transition for Complicated Urinary Tract Infections. Clinical Infectious Diseases. 2026;82(Supplement_3):i68-i78. doi:10.1093/cid/ciaf461

BibTeX
@article{Trautner2026,
  author = {Trautner, Barbara W and Cortés-Penfield, Nicolás W and Gupta, Kalpana and Hirsch, Elizabeth B and Horstman, Molly and Moran, Gregory J and Colgan, Richard and O'Horo, John C and Ashraf, Muhammad S and Connolly, Shannon and Drekonja, Dimitri and Grigoryan, Larissa and Huttner, Angela and Lazenby, Gweneth B and Nicolle, Lindsay and Schaeffer, Anthony and Yawetz, Sigal and Lavergne, Valéry},
  title = {Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections – Timing of Intravenous to Oral Antibiotics Transition for Complicated Urinary Tract Infections},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {82},
  number = {Supplement_3},
  pages = {i68--i78},
  doi = {10.1093/cid/ciaf461}
}
Kostenlos starten →